Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes

Launched by RADICLE SCIENCE · Dec 19, 2024

Keywords

ClinConnect Summary

The Radicle Revive™ 24 clinical trial is studying how health and wellness products can affect hormonal health and related issues in women who are experiencing menopause. This includes problems like sleep disturbances, anxiety, depression, fatigue, and changes in libido. The trial is currently recruiting women aged 21 and older who live in the United States and are interested in improving their health. Participants will receive either the actual product or a placebo—a fake treatment that looks the same—without knowing which one they have until the study is over.

To join the trial, participants should not be pregnant, breastfeeding, or have certain health conditions like liver or kidney disease. They also need to be willing to commit to the study and take the product as directed. Throughout the trial, participants can expect to provide feedback on their health and any changes they experience. This study aims to gather important information that could help improve the quality of life for women facing menopausal challenges.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities
• • Resides in the United States
• • Endorses less pain as a primary desire
• • Selects pain and/or looking to improve their pain as a reason for their interest in taking a health and wellness product
• • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
• Exclusion Criteria:
• • reports being pregnant, trying to become pregnant, or breastfeeding
• • Unable to provide a valid US shipping address and mobile phone number
• • The calculated validated health survey (PRO) score during enrollment represents less than mild severity
• • Reports a diagnosis of liver or kidney disease
• • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• • Unable to read and understand English
• • Reports current enrollment in a clinical trial
• • Lack of reliable daily access to the internet
• • Reports current or recent (within 3 months) use of chemotherapy or immunotherapy
• • Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied, or a substantial safety risk: Anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, or MAO